CD1.129S-Stat1+/Cnbc

Status

Available to order

EMMA IDEM:06064
International strain nameCD1.129S-Stat1+/Cnbc
Alternative nameCD1.129-Stat1<+/+>-Tg(APN)270<-/->/Cnbc
Strain typeTargeted Mutant Strains : Other targeted
Allele/Transgene symbolStat1+
Gene/Transgene symbolStat1

Information from provider

ProviderLuis Enjuanes
Provider affiliationCentro Nacional de Biotecnologia (CNB-CSIC)
Additional ownerThere are 14 strains of Stat1 KO available through IMSR, including the one used here from David Levy's lab at NYU (Stat1, MGI:1930947)
Genetic informationTransgenic mice were produced in ICR (CD1) mouse outbred background by standard pronuclear microinjection and bred to homozygosity. Stat1 KO mice were produced and donated by David Levy (NYU) in 129S/Sv (CCE ES cells) background and backcrossed to CD1 mouse background to homozygosity. A neomycin resistance cassette replaced 5.7 kb of sequence, including 3 exons and a portion of a fourth encoding amino acids 221-365. This allele produces a partial non-functional protein product. Both mouse lines were bred to double homozygosity in CD1 background. Line 270 and 861 expressed the highest levels of APN. These mice are double homozygous for non-transgenic line APN (wild-type) and double homozygous for Stat1 wild-type allele.
Phenotypic informationControl mice for the entire experiment.
Breeding historyStat1 KO mice originally generated in 129S/Sv background (CCE ES cells) and backcrossed to CD1. Tg APN mice generated in CD1(ICR) mice. Both mouse lines bred to double homozygous line. In this case Stat1 locus carries both wild-type alleles and there is no APN transgene.
References
  • Development of a transgenic mouse model susceptible to human coronavirus 229E.;Lassnig Caroline, Sanchez Carlos M, Egerbacher Monika, Walter Ingrid, Majer Susanne, Kolbe Thomas, Pallares Pilar, Enjuanes Luis, Müller Mathias, ;2005;Proceedings of the National Academy of Sciences of the United States of America;102;8275-80; 15919828
  • Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.;Durbin J E, Hackenmiller R, Simon M C, Levy D E, ;1996;Cell;84;443-50; 8608598
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedno

Information from EMMA

Archiving centreCNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

    • Autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome / Orphanet_391487
    • Susceptibility to viral and mycobacterial infections due to STAT1 deficiency / Orphanet_391311
    • Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency / Orphanet_319595
IMPC phenotypes (gene matching)
  • increased monocyte cell number / IMPC
  • decreased mean corpuscular hemoglobin / IMPC
  • increased neutrophil cell number / IMPC
  • increased lymphocyte cell number / IMPC
  • abnormal gait / IMPC
  • impaired righting response / IMPC
  • decreased mean corpuscular volume / IMPC
  • enlarged lymph nodes / IMPC
  • decreased lymphocyte cell number / IMPC
  • decreased bone mineral content / IMPC
  • increased leukocyte cell number / IMPC
  • decreased circulating alkaline phosphatase level / IMPC
  • increased large unstained cell number / IMPC
  • increased eosinophil cell number / IMPC
  • increased basophil cell number / IMPC
MGI phenotypes (gene matching)
  • abnormal intestine morphology / MGI
  • abnormal tibia morphology / MGI
  • decreased body size / MGI
  • abnormal cornea morphology / MGI
  • multifocal hepatic necrosis / MGI
  • abnormal T cell activation / MGI
  • decreased level of surface class I molecules / MGI
  • increased mammary adenocarcinoma incidence / MGI
  • no abnormal phenotype detected / MGI
  • increased susceptibility to bacterial infection / MGI
  • increased susceptibility to viral infection / MGI
  • abnormal leukocyte physiology / MGI
  • abnormal macrophage physiology / MGI
  • increased IgG level / MGI
  • increased myocardial infarction size / MGI
  • abnormal cell cycle / MGI
  • abnormal redox activity / MGI
  • increased cardiomyocyte apoptosis / MGI
  • abnormal nitric oxide homeostasis / MGI
  • increased compact bone thickness / MGI
  • decreased B-1 B cell number / MGI
  • increased osteoclast cell number / MGI
  • increased bone resorption / MGI
  • decreased B cell number / MGI
  • abnormal response to infection / MGI
  • abnormal MHC II cell surface expression on macrophages / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • immune system phenotype / MGI
  • vision/eye phenotype / MGI
  • abnormal T-helper 2 physiology / MGI
  • increased bone mass / MGI
  • abnormal cell physiology / MGI
  • abnormal common myeloid progenitor cell morphology / MGI
  • increased NK T cell number / MGI
  • decreased NK cell number / MGI
  • increased CD4-positive, alpha beta T cell number / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • decreased single-positive T cell number / MGI
  • decreased susceptibility to neuronal excitotoxicity / MGI
  • abnormal osteoblast differentiation / MGI
  • abnormal osteoclast differentiation / MGI
  • decreased interferon-gamma secretion / MGI
  • increased circulating interferon-gamma level / MGI
  • decreased circulating interferon-gamma level / MGI
  • increased circulating interleukin-12b level / MGI
  • decreased interleukin-1 beta secretion / MGI
  • decreased susceptibility to endotoxin shock / MGI
  • decreased NK cell degranulation / MGI
  • decreased hepatocyte apoptosis / MGI
  • decreased sensitivity to induced cell death / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • tumor regression / MGI
  • abnormal NK cell physiology / MGI
  • increased effector memory CD8-positive, alpha-beta T cell number / MGI
  • increased trabecular bone volume / MGI
  • increased compact bone volume / MGI
  • increased macrophage nitric oxide production / MGI
  • lethality at weaning, complete penetrance / MGI
  • abnormal CD8-positive, naive alpha-beta T cell number / MGI

Literature references

  • Development of a transgenic mouse model susceptible to human coronavirus 229E.;Lassnig Caroline, Sanchez Carlos M, Egerbacher Monika, Walter Ingrid, Majer Susanne, Kolbe Thomas, Pallares Pilar, Enjuanes Luis, Müller Mathias, ;2005;Proceedings of the National Academy of Sciences of the United States of America;102;8275-80; 15919828
  • Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.;Durbin J E, Hackenmiller R, Simon M C, Levy D E, ;1996;Cell;84;443-50; 8608598

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).